Trial Profile

Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GPC3-CAR-T (Primary) ; Cyclophosphamide; Fludarabine
Indications Liver cancer
Focus Adverse reactions; First in man

Most Recent Events

12 Oct 2023 According to a CARsgen media release, the results from this trial were published in the Cancer Communications.
12 Oct 2023 Results presented in the CARsgen Media Release.
05 May 2020 Results (n=13) of pooled analysis of two studies (NCT02395250 & NCT03146234) assessing feasibility and safety of CAR-GPC3 T-cell therapy in adult Chinese patients with advanced, published in the Clinical Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com